Cancer Research The Future of Cancer Research: Science and Patient Impact  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 54, 2334-2336, May 1, 1994]
© 1994 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ishiguro, Y.
Right arrow Articles by Ito, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ishiguro, Y.
Right arrow Articles by Ito, T.

The {alpha} Subunit of GTP-binding Protein Go in Neuroblastoma: Correlation with Advanced Disease Stage

Yukio Ishiguro1, Kanefusa Kato, Tomiko Asano, Hiroshi Akatsuka, Hiroyuki Iwata, Fujio Ito and Takahiro Ito

Department of Surgery, Branch Hospital of Nagoya University School of Medicine, Daiko-minami, Higashi-ku, Nagoya 461 [Y. I., H. A., H. I., F. I., T. I.], and Department of Biochemistry, Institute for Developmental Research, Aichi Prefectural Colony, Kamiya-cyo, Kasugai [K. K., T. A.], Japan

Tissue levels of the {alpha} subunit of G protein Go (Go {alpha}) were measured in solid tumors from pediatric patients by immunoassay. Go {alpha} concentrations were determined in the supernatant obtained by centrifugation of tissue homogenates prepared in the presence (total Go {alpha}) or absence of 2% sodium cholate (soluble Go {alpha}). Mean Go {alpha} concentrations (total Go {alpha} and soluble Go {alpha}) in neuroblastomas (7 ganglioneuromas, 13 ganglioneuroblastomas, and 50 neuroblastomas) were over 50-fold higher than those in other solid tumors from pediatric patients (n = 13). Mean total Go {alpha} and soluble Go {alpha} concentrations were 207.0 ± 166.0 (SD) ng/mg of cholate-extractable protein and 58.6 ± 47.0 ng/mg of soluble protein, respectively, in the neuroblastoma group (n = 70). Total Go {alpha} concentration decreased with disease stage and was strongly correlated with outcome in patients with neuroblastoma. The mean total Go {alpha} concentration in tumors from younger patients (<1 year old) was 297.0 ± 137.0 ng/mg of cholate-extractable protein, significantly higher than in tumors from older patients (140.0 ± 155.0 ng/mg cholate-extractable protein, P < 0.0001). These results suggest that total Go {alpha} levels in neuroblastoma may indicate the degree of malignancy.

1 To whom requests for reprints should be addressed.

Received 7/19/93. Accepted 3/ 2/94.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1994 by the American Association for Cancer Research.